Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Shingles vaccine reduces cardiovascular events

Written by | 15 May 2025

Results from a large South Korean study suggests that persons who are vaccinated to prevent shingles have a 23% lower risk of developing cardiovascular events, including stroke, heart… read more.

New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade – GSK

Written by | 26 Apr 2024

GSK plc announced positive data from the ZOSTER-049 long-term follow-up phase III trial which followed participants for up to approximately 11 years following initial vaccination with Shingrix (Recombinant… read more.

Shingrix for the prevention of shingles in at-risk adults aged 18 and over is accepted for review by China National Medical Products Administration – GSK

Written by | 16 Feb 2024

GSK plc announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted for review the regulatory application of Shingrix (Recombinant… read more.

MLHW (Japan) approves updated indication for Shingrix for the prevention of Shingles – GSK

Written by | 14 Jul 2023

GSK plc announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved an updated indication for Shingrix (Recombinant Zoster Vaccine, Adjuvanted – RZV) for the… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.